HCM
DMAA

Highbridge Capital Management’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

Highbridge Capital Management’s Portfolio DMAA Stock Details DMAA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.62M Sell
809,054
-514,297
-39% -$5.44M 0.21% 102
2026
Q1 		$13.9M Buy
+1,323,351
New +$13.8M 0.45% 47

Other funds holding DMAA

KIM
Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return
MSU
Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
SAMU
SONA Asset Management (US) New York $4.76B AUM 23.76% 1-Year Est. Return

Highbridge Capital Management's DMAA Position: Q2 2026 in Review

Highbridge Capital Management reduced its Drugs Made In America Acquisition Corp (DMAA) stake by 39% in Q2 2026, selling an estimated $5.44M and leaving 809,054 shares worth $8.62M. The position accounts for 0.21% of the portfolio, ranked #102.

Highbridge Capital Management first reported a position in DMAA in Q1 2026 and has held it in 2 quarters since. The position peaked at $13.9M in Q1 2026. 23 funds tracked by Wall St. Rank hold DMAA as of Q2 2026.

  • Highbridge Capital Management held 809,054 shares of Drugs Made In America Acquisition Corp worth $8.62M as of Q2 2026.
  • Highbridge Capital Management sold 514,297 Drugs Made In America Acquisition Corp shares in Q2 2026, an estimated $5.44M.
  • Drugs Made In America Acquisition Corp made up 0.21% of Highbridge Capital Management's portfolio in Q2 2026, its #102 holding.
  • Highbridge Capital Management first reported a position in Drugs Made In America Acquisition Corp in Q1 2026 and has held it in 2 quarters since.
  • Highbridge Capital Management's Drugs Made In America Acquisition Corp position peaked at $13.9M in Q1 2026.
  • 23 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q2 2026.

Based on Highbridge Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.